Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of
patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting. The
overall effectiveness of Aripiprazole will be evaluated by use of the Brief Psychiatric
Rating Scale(BPRS), Yale-Brown OCD scale and Clinical Global Impression-Improvement(CGI-I)
scale.
Phase:
N/A
Details
Lead Sponsor:
Jamaica Hospital Medical Center
Collaborators:
Bristol-Myers Squibb Department of Psychiatry, Jamaica Hospital Medical Center Research Division